MiamiHerald.com | 02/07/2007 | Surgery drug , Trasylol, worries doctors

MiamiHerald.com 02/07/2007 Surgery drug worries doctors: "Researchers compared patients who received aprotinin to patients who got other drugs or no anti-bleeding drugs. Over five years, 20.8 percent of the aprotinin patients died, versus 12.7 percent of the patients who received no anti-bleeding drug. When researchers adjusted for other factors, they found that patients who got Trasylol ran a 48 percent higher risk of dying in the five years afterward."

Trasylol is the trade name of aprotinin. Bayer has protested the study methods but more questions remain.